Search results: (10000)
News ESC 2022: Initiating Gliflozin in HFpEF During Hospitalization Can Benefit the Patient. This is Also Evidenced by Experience from the USA
Based on evidence from clinical studies, gliflozins are currently being introduced into practice for heart failure with preserved ejection fraction (HFpEF) as early as hospitalization. Sharing experiences is therefore very valuable. Several symposia at the ESC 2022 congress focused on the issue of introducing these drugs into HF treatment, some of which also included illustrative case studies. For example, the case of a patient with HFpEF from the USA demonstrated the early initiation of empagliflozin during hospitalization.
News Diagnosis of AHA Requires Laboratory Testing – What Are Its Key Specifics?
Acquired hemophilia A (AHA) is a rare but very serious disease with a high mortality rate. Quick and accurate diagnosis is crucial, but according to RNDr. Ingrid Hrachovinová, Ph.D., from the Institute of Hematology and Blood Transfusion in Prague (ÚHKT), it requires sufficient information and experience. In her lecture on this topic at the XXVIII. Czech-Slovak Conference on Thrombosis and Hemostasis held together with the XX. Czech-Slovak Conference on Laboratory Hematology in mid-September in Hradec Králové, she provided a number of useful guidelines for practice.
News ESC 2022: Can Modern Treatment of Acute Heart Failure Improve (Re)hospitalization Prevention?
Heart failure (HF) and the possibilities of its therapy were one of the frequently discussed topics at this year's annual congress of the European Society of Cardiology (ESC 2022), which took place at the end of August in Barcelona. The potential of current approaches in reducing the risk of hospitalization or rehospitalization due to HF was also discussed. In summary, we present the insights from a symposium focused directly on this issue.
News Rapid Strengthening and Long-term Stabilization – New Strategy for Sequential Treatment of Severe Osteoporosis
Osteoanabolics have long been considered a treatment modality for osteoporosis that is only considered when antiresorptive medication lacks the desired efficacy. However, their role has been shifting in recent years based on new findings from clinical research, as evidenced by the conclusions of the expert working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO), whose brief summary we bring.
News Pain Management in Patients After Hip and Knee Arthroplasty – Data from Clinical Practice
Inadequate analgesia after hip and knee arthroplasty can result in delayed postoperative recovery accompanied by chronic pain. The retrospective study presented below compared the efficacy of analgesia via continuous epidural infusion of ropivacaine, patient-controlled IV analgesia with the so-called Würzburg drip, and piritramide.
News INTERACTIVE CASE STUDY: Treatment of glaucoma medications without preservatives – current trend
The use of glaucoma medications without preservatives has been a trend in recent years. You can try their clinical application in the role of a prescribing doctor in an interactive case study. Practical information about this popular local treatment is based on the evidence-based medicine foundation, provided by its author MUDr. Petr Výborný, CSc., from the Eye Clinic of the 1st Faculty of Medicine, Charles University and University Military Hospital in Prague.
News Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.
News Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment – Case Study
In patients with immune thrombocytopenia (ITP), effectively stopping and controlling bleeding can be complicated in some cases. This includes scenarios such as open wounds. One way to stabilize platelet count can be through administering a thrombopoietin receptor agonist (TPO-RA). The following case study presents a successful treatment of newly diagnosed ITP.
News Romiplostim in ITP Treatment – Data from German Clinical Practice
Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and chronic.
News Invasive Pneumococcal Disease – Current Czech Data
The number of reported cases of invasive pneumococcal disease (IPD) returned to levels comparable to those before the COVID-19 pandemic in 2022. Regarding age-specific morbidity, the most at-risk groups are children under 1 year of age and seniors over 65 years old. The specific data for 2022 is provided by a report from the Center for Epidemiology and Microbiology of the National Institute of Public Health (SZÚ).
News Physical Activity in Young Men with Hemophilia A
What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.
News N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up
An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
News Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia
Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with schizophrenia and schizoaffective disorders perceive antipsychotic treatment, a larger survey was conducted in the USA in 2016.
News Ocrelizumab in the treatment of multiple sclerosis in real-world practice – a systematic review of published studies
In controlled study programs, ocrelizumab has demonstrated beneficial effects on improving clinical parameters in patients with multiple sclerosis, such as the annual relapse rate or confirmed disability progression. However, to get a complete picture of its clinical benefit, real-world evidence in a broad patient population is also needed. A systematic review of real-world clinical practice studies with ocrelizumab, published in March 2023, demonstrates its benefits in patients with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in terms of relapse frequency, disease activity on MRI, disability, absence of disease activity (NEDA), and quality of life.
News INFOGRAPHIC: Post-Induction Therapy for AML – Current Guidelines
What are the recommended therapeutic modalities for consolidation and maintenance therapy of acute myeloid leukemia (AML) in patients over 60 years of age? We present a clear therapeutic algorithm according to the current recommendations of the American National Comprehensive Cancer Network.